Valeant Acquires Amarin’s U.S. Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant adds the Parkinson's therapy Permax (pergolide) to its CNS business with the acquisition of Amarin Corp.'s U.S. pharma business, announced Feb. 12
You may also be interested in...
Amarin Plans Additional Phase III Trial For Miraxion To Support Huntington's NDA
London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.
Amarin Plans Additional Phase III Trial For Miraxion To Support Huntington's NDA
London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.
Valeant's Permax No Longer Permitted In The U.S. For Parkinson's Disease
FDA announces voluntary withdrawal of the pergolide brand and two generics due to high rates of cardiac valvulopathy.